News Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch October 16, 2019 / 0 Comments Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch October 16, 2019 / 0 Comments GCAM Adds New Plasma Collection Centers November 9, 2018 / 0 Comments GC Pharma Marks ‘World Haemophilia Day’ April 16, 2018 / 0 Comments Green Cross Introduces Its New Master Brand “GC” January 2, 2018 / 0 Comments Québec marks the inauguration of the Green Cross Biotherapeutics facilities in Montréal October 30, 2017 / 0 Comments Green Cross Biotherapeutics inaugurates its state-of-the-art facility in Montreal October 30, 2017 / 0 Comments GCBT Submission to Canada’s Innovation Agenda December 22, 2016 / 0 Comments Green Cross Biotherapeutics Supports Montreal Children’s Hospital Foundation April 4, 2016 / 0 Comments Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10% March 7, 2016 / 0 Comments Related Articles Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch October 16, 2019 / 0 Comments Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch October 16, 2019 / 0 Comments Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch October 16, 2019 / 0 Comments GC Pharma Marks ‘World Hemophilia Day’ April 15, 2019 / 0 Comments Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug April 3, 2019 / 0 Comments CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome January 7, 2019 / 0 Comments Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate November 9, 2018 / 0 Comments GC Pharma Receives Korea’s MFDS Approval of GCFLU Quadrivalent (Influenza Vaccine) for persons 6 months and older October 1, 2018 / 0 Comments GC LabCell and Feldan Therapeutics announce license agreement to develop next-generation NK cells for immunotherapy using Feldan Shuttle technology June 27, 2018 / 0 Comments GC Pharma to Establish Curevo – a Seattle-based New Company Dedicated to Development of New Vaccines May 20, 2018 / 0 Comments
